MX2017009325A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX2017009325A
MX2017009325A MX2017009325A MX2017009325A MX2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A MX 2017009325 A MX2017009325 A MX 2017009325A
Authority
MX
Mexico
Prior art keywords
methods
levodopa
pharmaceutical composition
intestinal gel
carbidopa
Prior art date
Application number
MX2017009325A
Other languages
English (en)
Inventor
Huang Ye
E Mackey Sean
Conjeevaram Rajkumar
Deac Alexandru
A Menges Randy
B Zimmerman Jayne
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017009325A publication Critical patent/MX2017009325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente divulgación se refiere a (a) una composición farmacéutica mejorada que comprende un agente activo de levodopa y un agente activo de carbidopa, (b) métodos de producir la composición farmacéutica y (c) métodos de tratar la enfermedad de Parkinson y afecciones asociadas, que comprende administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2017009325A 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso. MX2017009325A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105565P 2015-01-20 2015-01-20
US201562272922P 2015-12-30 2015-12-30
PCT/US2016/014005 WO2016118556A1 (en) 2015-01-20 2016-01-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (1)

Publication Number Publication Date
MX2017009325A true MX2017009325A (es) 2018-02-09

Family

ID=55410198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009325A MX2017009325A (es) 2015-01-20 2016-01-20 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (16)

Country Link
US (3) US10117843B2 (es)
EP (1) EP3247330A1 (es)
JP (3) JP2018503686A (es)
KR (1) KR20170103967A (es)
CN (2) CN116036064A (es)
AU (1) AU2016209420B2 (es)
BR (1) BR112017015613B1 (es)
CA (1) CA2974203A1 (es)
IL (1) IL253487A0 (es)
MA (1) MA41377A (es)
MX (1) MX2017009325A (es)
PH (1) PH12017501304A1 (es)
RU (1) RU2017129375A (es)
SG (1) SG11201705964YA (es)
TW (1) TW201639556A (es)
WO (1) WO2016118556A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
EP3487479A1 (en) * 2016-07-20 2019-05-29 AbbVie Inc. Levodopa and carbidopa intestinal gel and methods of use
JP7314871B2 (ja) 2020-07-09 2023-07-26 新東工業株式会社 強度計測装置及び強度計測方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
EP2063865A1 (en) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
LT2432454T (lt) 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
NZ601747A (en) 2009-11-09 2014-08-29 Xenoport Inc Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
ES2833276T3 (es) * 2011-08-31 2021-06-14 Abbvie Inc Disposión de sellado para jeringa
HRP20211442T1 (hr) 2013-03-13 2022-02-04 Neuroderm Ltd Kombinacija za liječenje parkinsonove bolesti
AU2014346855B2 (en) 2013-11-05 2019-07-18 Synagile Corporation Devices and methods for continuous drug delivery via the mouth

Also Published As

Publication number Publication date
RU2017129375A (ru) 2019-02-21
US20210046029A1 (en) 2021-02-18
AU2016209420A1 (en) 2017-08-03
CN116036064A (zh) 2023-05-02
TW201639556A (zh) 2016-11-16
US20190142777A1 (en) 2019-05-16
KR20170103967A (ko) 2017-09-13
MA41377A (fr) 2017-11-28
JP2023058678A (ja) 2023-04-25
BR112017015613A2 (pt) 2018-03-13
EP3247330A1 (en) 2017-11-29
SG11201705964YA (en) 2017-08-30
IL253487A0 (en) 2017-09-28
JP2018503686A (ja) 2018-02-08
JP2021073186A (ja) 2021-05-13
CA2974203A1 (en) 2016-07-28
US20160206584A1 (en) 2016-07-21
US10117843B2 (en) 2018-11-06
BR112017015613B1 (pt) 2023-11-28
JP7232235B2 (ja) 2023-03-02
RU2017129375A3 (es) 2019-08-05
CN107427463A (zh) 2017-12-01
PH12017501304A1 (en) 2018-02-05
WO2016118556A1 (en) 2016-07-28
AU2016209420B2 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
MY188139A (en) Sodium channel modulators for the treatment of pain
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
PH12020500321A1 (en) Amino acid compositions for the treatment of liver disease
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
MX2021002321A (es) Nuevos metodos.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2021007486A (es) Hidrolizado de colageno para usarse con trastornos de la piel y trastornos intestinales.
WO2018128722A8 (en) Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease
MX2018004984A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
ZA202006986B (en) Dantrolene formulations and methods of their use
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
IN2014MU01185A (es)
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
IN2014MU01184A (es)
IN2013MU02575A (es)